vitamin D levels associated with survival in lymphoma patients

Published: Saturday, December 5, 2009 - 17:29 in Health & Medicine
A new study has found that the amount of vitamin D (http://www.mayoclinic.org/news2008-mchi/4904.html) in patients being treated for diffuse large B-cell lymphoma (http://www.mayoclinic.org/non-hodgkins-lymphoma/)was strongly associated with cancer progression and overall survival. The results will be presented at the annual meeting of the American Society of Hematology (http://www.hematology.org/) in New Orleans. "These are some of the strongest findings yet between vitamin D and cancer outcome," says the study's lead investigator, Matthew Drake, M.D., Ph.D., (http://www.mayoclinic.org/bio/13726218.html) an endocrinologist at Mayo Clinic in Rochester. "While these findings are very provocative, they are preliminary and need to be validated in other studies. However, they raise the issue of whether vitamin D supplementation might aid in treatment for this malignancy, and thus should stimulate much more research."

The researchers' study of 374 newly diagnosed diffuse large B-cell lymphoma patients found that 50 percent had deficient vitamin D levels based on the commonly used clinical value of total serum 25(OH)D less than 25 ng/mL. Patients with deficient vitamin D levels had a 1.5-fold greater risk of disease progression and a twofold greater risk of dying, compared to patients with optimal vitamin D levels after accounting for other patient factors associated with worse outcomes.

The study was conducted by a team of researchers from Mayo Clinic and the University of Iowa. These researchers participate in the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE), (http://mayoresearch.mayo.edu/mayo/research/hematologic_malignancies/spore_lymphoma.cfm) which is funded by the National Cancer Institute. The 374 patients were enrolled in an epidemiologic study designed to identify predictors of outcomes in lymphoma. Since this was not a clinical trial, patient management and treatments were not assigned, but rather followed standard of care for clinical practice.

The findings support the growing association between vitamin D and cancer risk and outcomes, and suggest that vitamin D supplements might help even those patients already diagnosed with some forms of cancer, says Dr. Drake. "The exact roles that vitamin D might play in the initiation or progression of cancer is unknown, but we do know that the vitamin plays a role in regulation of cell growth and death, among other processes important in limiting cancer," he says.

more:
http://esciencenews.com/articles/2009/12/05/mayo.clinic.and.collaborators.find.vitamin.d.levels.associated.with.survival.lymphoma.patients

I agree, and this is good research. But what about us melanoma survivors? Which BTW could be a cheap research study. I never go out during daylight if I can avoid it Get my Vit D from tablets and milk.

Citation:
J Clin Oncol 27:15s, 2009 (suppl; abstr 9016)


Author(s):
J. A. Newton Bishop, S. Beswick, J. Randerson-Moor, Y. Chang, P. Affleck, F. Elliott, D. Elder, J. Barrett, T. Bishop; University of Leeds, Leeds, United Kingdom; University of Pensylvania, Philadelphia, PA

Abstract:


Background: Vitamin D has pleiotropic effects, which may moderate the interaction between patients and their tumors. Two studies were carried out to test the hypothesis that higher vitamin D levels reduce the risk of relapse from melanoma. Methods: A pilot retrospective case-control study in 271 melanoma patients suggested that vitamin D may protect against recurrence of melanoma. We then tested these findings in a survival analysis in a cohort of 872 cases recruited to the Leeds Melanoma Cohort (median follow up of 4.7 years). Results: Pilot study Results suggested that taking vitamin D reduced the risk of relapse from melanoma (OR 0.6, 95% CI: 0.4, 1.1). Non-relapsers had higher mean 25-dihydroxyvitamin D3 levels than relapsers (49 nmol/L compared with 46, p=0.3). Cohort study Higher 25-dihydroxyvitamin D3 levels were associated with lower Breslow thickness at diagnosis and were independently protective of relapse and death: hazard ratio (HR) for relapse free survival (RFS) 0.76, 95% CI: (0.64, 0.96), for a 20nmol/L increase in serum level. There was evidence of interaction between the vitamin D receptor (VDR) BsmI genotype and serum 25-dihydroxyvitamin D3 levels on RFS. Conclusions: The pilot study provided preliminary evidence for a role for vitamin D in outcome from melanoma. The cohort study provided further evidence that higher 25-dihydroxyvitamin D3 levels, at diagnosis, were associated both with thinner tumors and better survival, independent of Breslow thickness, from melanoma. Melanoma patients should avoid vitamin D deficiency. Further studies are needed to establish optimal serum levels for melanoma patients.





http://pda.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30491



It looks like Vitamin D is protective. The important thing is to have your level tested. FYI the above article uses SI measurement whereas US labs use Conventional Units: ng/L

To convert nmol to ng/L

Divide nmol by 2.496

But in the case of melanoma, get your vitamin D up from supplements and food, not uncontrolled sun exposure.